Niacin and Ezetimibe/Simvastatin Interaction

Understanding the Niacin and Ezetimibe/Simvastatin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Niacin belongs to the Vitamin B3 (Lipid-Modifying) class and Ezetimibe/Simvastatin belongs to the Cholesterol Absorption Inhibitor / Statin Combination class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Taking high doses of niacin with this drug increases the risk of muscle damage and may not provide extra heart benefits. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Niacin has 21 total documented interactions on file in this dataset, and Ezetimibe/Simvastatin has 23. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: This combination is generally not recommended, particularly for Chinese patients, due to the risk of muscle problems. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Niacin or Ezetimibe/Simvastatin based on a web page, speak with your prescriber or pharmacist before making any change.